Skip to search formSkip to main contentSkip to account menu

androgen independent prostate cancer

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
AIM To investigate the expression of cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) and the possible… 
2008
2008
Cilengitide in asymptomatic metastatic androgen independent prostate cancer (AIPC) patients (pts): A randomized phase II trial
5144 Background: Integrins αvβ3 and αvβ5 are involved in PC metastasis by regulating cell adhesion, migration, invasion, motility… 
Review
2007
Review
2007
Predictive variables of the progression to androgen independent prostate cancer after combined androgen blockade
Purpose: Despite of the effectiveness of androgen deprivation therapy for prostate cancer, it progress to androgen independent… 
2006
2006
Phase II Evaluation of Docetaxel Plus Exisulind in Patients With Androgen Independent Prostate Carcinoma
Objectives:In this phase II study, the combination of docetaxel and exisulind (a GMP phosphodiesterase inhibitor) was given to… 
2006
2006
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.
The focus of this study was to evaluate the therapeutic benefit of combined gastrin-releasing peptide (GRP) receptor-targeted… 
Review
2006
Review
2006
Changing perspectives of the role of chemotherapy in advanced prostate cancer.
2006
2006
Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC).
4560 Background: Estrogens, including DES, transdermal estradiol, estramustine and PC-SPES, have shown antitumor activity in AIPC… 
2006
2006
A phase II study utilizing oxaliplatin and docetaxel in androgen independent prostate cancer in men treated with up to two prior chemotherapy regimens.
14580 Background: Second line treatment of androgen independent prostate cancer (AIPC) is unsatisfactory. Single agent docetaxel… 
Highly Cited
2005
Highly Cited
2005
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
PURPOSE Alendronate (AL), a potent oral bisphosphonate, blocks the secretion of matrix metalloproteinase-2 and the establishment… 
Review
2004
Review
2004
The natural history of androgen independent prostate cancer.
PURPOSE We describe the natural history of androgen independent prostate cancer (AIPC) in the modern prostate specific antigen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)